Literature DB >> 24799306

Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).

Sanjeev Sethi1, Fernando C Fervenza2.   

Abstract

Dysfunction of the alternative pathway of complement in the fluid phase results in deposition of complement factors in the renal glomeruli. This results in glomerular injury and an ensuing proliferative response. The term "C3 glomerulopathy" is used to define such an entity. It includes both C3 glomerulonephritis and dense deposit disease (DDD). Both C3 glomerulonephritis and DDD are characterized by a proliferative glomerulonephritis and bright glomerular C3 mesangial and capillary wall staining with the absence or scant staining for immunoglobulins (Ig). The two conditions are distinguished based on electron microscopy findings: mesangial and capillary wall deposits are noted in C3 glomerulonephritis, while ribbon-shaped dense osmiophilic intramembranous and mesangial deposits are noted in DDD. On the contrary, uncontrolled activation of the alternative pathway of complement on endothelial cell surface results in endothelial injury with an ensuing thrombotic microangiopathy, termed atypical hemolytic uremic syndrome (aHUS). Kidney biopsy in aHUS is often indistinguishable from other forms of thrombotic microangiopathy including enterohemorrhagic Escherichia coli-induced HUS and thrombotic thrombocytopenic purpura and shows thrombi in glomerular capillaries, mesangiolysis, and endothelial injury as evidenced by swelling and double contour formation along the glomerular capillary walls, with negative immunofluorescence studies for Ig and complement factors and no deposits on electron microscopy. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24799306     DOI: 10.1055/s-0034-1375701

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  25 in total

1.  A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

Review 2.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

Review 3.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

4.  Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.

Authors:  Khalid Alfakeeh; Mohammed Azar; Majid Alfadhel; Alsuayri Mansour Abdullah; Nourah Aloudah; Khaled O Alsaad
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

5.  Circulating complement levels and C3 glomerulopathy.

Authors:  Fernando C Fervenza; Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

Review 6.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

7.  Complement Activation and Thrombotic Microangiopathies.

Authors:  Marta Palomo; Miquel Blasco; Patricia Molina; Miquel Lozano; Manuel Praga; Sergi Torramade-Moix; Julia Martinez-Sanchez; Joan Cid; Gines Escolar; Enric Carreras; Cristina Paules; Fatima Crispi; Luis F Quintana; Esteban Poch; Lida Rodas; Emma Goma; Johann Morelle; Mario Espinosa; Enrique Morales; Ana Avila; Virginia Cabello; Gema Ariceta; Sara Chocron; Joaquin Manrique; Xoana Barros; Nadia Martin; Ana Huerta; Gloria M Fraga-Rodriguez; Mercedes Cao; Marisa Martin; Ana Maria Romera; Francesc Moreso; Anna Manonelles; Eduard Gratacos; Arturo Pereira; Josep M Campistol; Maribel Diaz-Ricart
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

Review 8.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

9.  Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.

Authors:  Yuzhou Zhang; Dingwu Shao; Daniel Ricklin; Brieanna M Hilkin; Carla M Nester; John D Lambris; Richard J H Smith
Journal:  Immunobiology       Date:  2015-05-05       Impact factor: 3.144

10.  Acute kidney injuries induced by thrombotic microangiopathy following severe hemorrhage in puerperants: a case series and literature review.

Authors:  Xu Wang; Chun-Yan Liu; Yue Yang; Gu-Ming Zou; Li Zhuo; Su-Hui Han; Wen-Ge Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.